Anti-Hypertension Drug Therapy Flashcards
(47 cards)
Most patient will require more than
one BP medication to reach goal BP
Initial Therapy
Thiazide-type diuretics
Angiotensin-converting enzyme (ACE)inhibitors/angiotensinII receptor blockers (ARBs)
Calcium channel blockers
First line therapy for HF and HTN
diuretics
reduces extracellular flid
diuretics
ADR for Diuretics
electrolyte imbalance
drug interactions diruetics
protentional additive hypotensive effects with other drugs that lower BP
Diuretics’ MOA
Blockade of sodium and chloride reabsorption
Diuretics site of action
Proximal tubule produces greatest diuresis
Diuretics adverse effects
Hypovolemia
Acid-base imbalance
Electrolyte imbalances
Classifications of Diuretics
Thiazide diuretics
Loop diuretics
Potassium sparing diuretics
Loop Diuretic Example
Furosemide, bumetanide, torsemide
Potassium-Sparing Diuretics useful response
Useful responses
Modest increase in urine production
Substantial decrease in potassium excretion
Potassium-Sparing Diuretics are rarely used
Rarely used alone for therapy
Potassium-Sparing Diuretics example
Amiloride,triamterene,spironolactone, andeplerenone
Potassium-Sparing Diuretics act on
Primary used in combination with a loop or thiazide diuretic
Potassium-Sparing Diuretics primary used in combination with
combination with a loop or thiazide diuretic
Potassium-Sparing Diuretics monitor
serum potassium
Spironolactone is a
Aldosterone antagonist
Spironolactone MOA
Blocks aldosterone in the distal nephron
Retention of potassium
Increased excretion of sodium
Spironolactone Uses
Edematous states Heart failure (decreases mortality in severe failure) Primary hyperaldosteronism Premenstrual syndrome Polycystic ovary syndrome Acne in young women
Spironolactone ADR
Hyperkalemia
Benign and malignant tumors
Endocrine effects
Interactions
Thiazide and loop diuretics
Agents that raise potassium levels
ACE Effects and MOA
Reduce levels of angiotensin II
Increase levels of bradykinin
ACE Use
HTN, HF, MI, diabetic and non-diabetic nephropathy; prevention of MI, stroke, and death in patients at high CV risk